![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the agreement, BWXT Medical, will provide Fusion with a preferential supply of radium-225 and access to high-specific activity generator technology, enabling Fusion for advancing its pipeline of targeted alpha therapies.
Lead Product(s): Actinium-225
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Fusion Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Expanded Collaboration November 16, 2023
Details:
[111In]-FPI-1547 is a targeted radioimmuno-imaging agent that consists of FPI-1175, an insulin-like growth factor-1 receptor (IGF-1R)-targeting humanized monoclonal antibody, a bifunctional chelate, and Indium-111, a radionuclide.
Lead Product(s): [225Ac]-FPI-1434
Therapeutic Area: Oncology Product Name: [225Ac]-FPI-1434
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Recipient: Fusion Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement January 05, 2023
Details:
Under the terms of the commercial agreement, Bayer will purchase high-purity Ac-225 from BWXT Medical at pre-determined prices. Ac-225 is a highly powerful radioisotope used in targeted alpha therapies (TATs).
Lead Product(s): Acc-225
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Large molecule
Partner/Sponsor/Collaborator: Bayer AG
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement June 27, 2022
Details:
TRIUMF will irradiate thorium-232 targets for BWXT Medical. From this irradiated thorium, BWXT Medical will process and produce high purity n.c.a Ac-225, sometimes referred to as non-carrier-added Ac-225, for commercial sale, strengthening BWXT Medical’s position.
Lead Product(s): n.c.a Ac-225
Therapeutic Area: Oncology Product Name: n.c.a Ac-225
Highest Development Status: UndisclosedProduct Type: Small molecule
Partner/Sponsor/Collaborator: TRIUMF
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement June 13, 2022